Investor'snote

At MindReader, we’ve been digging into some promising early-science oncology and immune-focused pipelines. Names like: BDTX, IMRX, ORKA, RVMD, VSTM, ELTX, CLYM, NUVB, REPL, OLMA, NKTR are being considered for initiating overweight positions in these issues for the long run.